Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER public affairs office

Executive Summary

FDA's Center for Biologic Evaluation and Research is establishing a new division, under the Office of Compliance, called the Division of Congressional and Public Affairs. Starting Dec. 5, the division will be headed by current chief of the Freedom of Information Office (under the Center for Drugs) Mark Elengold. The division, which will serve as a liaison to Congress and respond to requests for information about activities in Biologics, is expected to have a staff of 15 - seven from existing Fol positions in Biologics and eight new staffers. Fol staffer CarolAnn Wooton will move into Elengold's spot on an acting basis....
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel